Congenital nephrotic syndrome responsive to captopril and indometacin

Area of Science:

• Pediatric Nephrology
• Clinical Pharmacology

Background:

• Congenital nephrotic syndrome (CNS) presents a significant challenge in pediatric nephrology.
• Finnish-type nephrosis and diffuse mesangial sclerosis are distinct forms of CNS requiring effective management.

Observation:

• Two pediatric patients diagnosed with congenital nephrotic syndrome were treated.
• The treatment regimen exclusively utilized captopril and indometacin.
• Clinical observations focused on treatment response, physical health, and growth patterns.

Findings:

• Both children exhibited a prolonged and sustained clinical response to captopril and indometacin.
• Patients maintained good physical health and normal growth trajectories during treatment.
• No adverse effects were reported during the course of the therapy.

Implications:

• Captopril and indometacin demonstrate potential as a sole therapeutic strategy for congenital nephrotic syndrome.
• This combination therapy warrants consideration for clinical trials in managing CNS.
• Further research may validate this approach for improving outcomes in affected children.